Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease

Authors Information
Article Notes and Dates
To Cite : Fallatah H I, Akbar H O, Fallatah A M. Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease, Hepat Mon. 2016 ;16(7):e38346. doi: 10.5812/hepatmon.38346.
Copyright: Copyright © 2016, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6): 2005-23[DOI][PubMed]
  • 2. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010; 51(2): 595-602[DOI][PubMed]
  • 3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011; 43(8): 617-49[DOI][PubMed]
  • 4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34(3): 274-85[DOI][PubMed]
  • 5. Chen ZW, Chen LY, Dai HL, Chen JH, Fang LZ. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B. 2008; 9(8): 616-22[DOI][PubMed]
  • 6. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1): 113-21[PubMed]
  • 7. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008; 49(4): 608-12[DOI][PubMed]
  • 8. Li H, Wang YJ, Tan K, Zeng L, Liu L, Liu FJ, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int. 2009; 8(4): 377-82[PubMed]
  • 9. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009; 57: 205-10[PubMed]
  • 10. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009; 29(1): 113-9[DOI][PubMed]
  • 11. Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care. 2003; 26(12): 3351-2[PubMed]
  • 12. Al-hamoudi W, El-Sabbah M, Ali S, Altuwaijri M, Bedewi M, Adam M, et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med. 2012; 32(3): 288-92[DOI][PubMed]
  • 13. Fallatah HI. Noninvasive biomarkers of liver fibrosis: an overview. Adv Hepatol. 2014; 2014
  • 14. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013; 58(5): 1007-19[DOI][PubMed]
  • 15. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011; 53(3): 726-36[DOI][PubMed]
  • 16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2): 518-26[DOI][PubMed]
  • 17. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006; 43(6): 1317-25[DOI][PubMed]
  • 18. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59(9): 1265-9[DOI][PubMed]
  • 19. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128(2): 343-50[PubMed]
  • 20. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010; 51(2): 454-62[DOI][PubMed]
  • 21. Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis. 2010; 19(1): 53-60[PubMed]
  • 22. Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci. 2013; 58(1): 265-74[DOI][PubMed]
  • 23. Friedrich-Rust M, Hadji-Hosseini H, Kriener S, Herrmann E, Sircar I, Kau A, et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol. 2010; 20(10): 2390-6[DOI][PubMed]
  • 24. de Ledinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010; 30(7): 1043-8[DOI][PubMed]
  • 25. Akbar HO, Fallatah HI. Serum ALT levels in a cohort of healthy blood donors and volunteers from Saudi Arabia: the influence of sex and body mass index. Gastroentol Hepatol. 2010; 1: 13-9
  • 26. Poordad F. Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007; 26 Suppl 1: 5-11[DOI][PubMed]
  • 27. Hancox SH, Smith BC. Liver disease as a cause of thrombocytopenia. QJM. 2013; 106(5): 425-31[DOI][PubMed]
  • 28. Yoneda M, Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007; 56(9): 1330-1[DOI][PubMed]
  • 29. Yoneda M, Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis. 2008; 40(5): 371-8[DOI][PubMed]
  • 30. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harthi SS, Arafah MR, Khalil MZ, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004; 25(11): 1603-10[PubMed]
  • 31. Alqurashi KA, Aljabri KS, Bokhari SA. Prevalence of diabetes mellitus in a Saudi community. Ann Saudi Med. 2011; 31(1): 19-23[DOI][PubMed]
  • 32. al-Nuaim AR, al-Rubeaan K, al-Mazrou Y, al-Attas O, al-Daghari N, Khoja T. High prevalence of overweight and obesity in Saudi Arabia. Int J Obes Relat Metab Disord. 1996; 20(6): 547-52[PubMed]
  • 33. Al-Nozha MM, Al-Mazrou YY, Al-Maatouq MA, Arafah MR, Khalil MZ, Khan NB, et al. Obesity in Saudi Arabia. Saudi Med J. 2005; 26(5): 824-9[PubMed]
  • 34. Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 513-20[PubMed]
  • 35. Shimizu I. Chronic hepatitis C and B progress more slowly in females than males. In: Female hepatology: favorable role of female factors in liver disease. 2009; : 17-28
  • 36. Miyagi Y, Ishii Y, Nitta T, Ochi M, Shimizu K. Electrophysiological and histological assessment of transmurality after epicardial ablation using unipolar radiofrequency energy. J Card Surg. 2009; 24(1): 34-40[DOI][PubMed]
  • 37. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1): 1-10[PubMed]
  • 38. Fallatah HI, Akbar HO. Lack of correlation between serum alanine amino transferrase and abdominal ultrasound in the diagnosis non alcoholic fatty liver disease in type 2 diabetes. Int J Diabetes Metab. 2010; 18: 120-3
  • 39. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010; 103(2): 71-83
  • 40. Tilg H. Adipocytokines in nonalcoholic fatty liver disease: key players regulating steatosis, inflammation and fibrosis. Curr Pharm Des. 2010; 16(17): 1893-5[PubMed]
  • 41. Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines. Medicine (Baltimore). 2016; 95(5)[DOI][PubMed]
  • 42. Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem. 2011; 26(2): 202-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check